BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 24372659)

  • 1. The role of primary antifungal prophylaxis in patients with haematological malignancies.
    Pagano L; Caira M
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
    Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
    J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
    Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
    J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
    Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
    Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
    Salavert M; Jarque I
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
    Rogers TR; Slavin MA; Donnelly JP
    Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies.
    Zeng H; Wu Z; Yu B; Wang B; Wu C; Wu J; Lai J; Gao X; Chen J
    BMC Cancer; 2021 Apr; 21(1):404. PubMed ID: 33853560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B
    Transplant Proc; 2013; 45(1):407-14. PubMed ID: 23375330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
    Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
    Rely K; Alexandre PK; Escudero GS
    Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.